PepGen Inc. (PEPG)
NASDAQ: PEPG · Real-Time Price · USD
4.890
+0.010 (0.20%)
At close: Mar 26, 2026, 4:00 PM EDT
4.880
-0.010 (-0.20%)
After-hours: Mar 26, 2026, 7:43 PM EDT
Company Description
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.
The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
PepGen Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | May 6, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 56 |
| CEO | James McArthur |
Contact Details
Address: 321 Harrison Avenue, 8th Floor Boston, Massachusetts 02118 United States | |
| Phone | 781 797 0979 |
| Website | pepgen.com |
Stock Details
| Ticker Symbol | PEPG |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 1835597 |
| CUSIP Number | 713317105 |
| ISIN Number | US7133171055 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James G. McArthur Ph.D. | President, Chief Executive Officer, Treasurer, Secretary and Director |
| Noel P. Donnelly M.B.A. | Chief Financial Officer |
| Dr. Paul D. Streck M.B.A., M.D. | Executive Vice President and Head of Research and Development |
| Dr. Kasra Kasraian Ph.D. | Chief Technology Officer |
| Emiko Bryant | Senior Vice President of Human Resources and Administration |
| Joseph D. Vittiglio Esq., J.D. | Chief Business and Legal Officer |
| Dr. Hayley Parker Ph.D. | Senior Vice President of Global Regulatory Affairs and Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 11, 2026 | SCHEDULE 13G | Filing |
| Mar 4, 2026 | 8-K | Current Report |
| Mar 4, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 4, 2026 | 10-K | Annual Report |
| Mar 4, 2026 | 8-K | Current Report |
| Dec 8, 2025 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 12, 2025 | 8-K | Current Report |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 7, 2025 | 8-K | Current Report |